Evidence map›Paper›PMID 40099382›Full record

Trial reportJournal of cosmetic dermatology2025

A Split-Face Micro-Needling Study to Evaluate the Efficacy and Consumer Perception of a Novel Moisturization Agent.

Tahreem Nawaz, Jinseob Shin, Michelle Shieh, Jane Y Yoo

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07774260 (Efficacy Validation of Deep Microspicule Cream for Anti-aging and Whitening on Mature Skin), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07774260 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Efficacy Validation of Deep Microspicule Cream for Anti-aging and Whitening on Mature Skin

TypeinterventionalSponsorChung Shan Medical UniversityRan2026 to 2026Enrolled10ConditionsEfficacy Validation of Deep Microspicule Cream for Anti-aging and Whitening on Mature SkinArmsDeep Microspicule Cream
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tahreem NawazClinical Research Center of New York, New York, New York, USA.ORCID https://orcid.org/0009-0002-9786-4317
Jinseob ShinAMOREPACIFIC US, Inc., New York, New York, USA.
Michelle ShiehAMOREPACIFIC US, Inc., New York, New York, USA.
Jane Y YooClinical Research Center of New York, New York, New York, USA.ORCID https://orcid.org/0000-0002-7112-8963

Funding

Amorepacific Corporation
6 · The paper itself

Abstract

backgroundWound healing is essential for restoring skin integrity following damage. The skin barrier plays a critical role in protecting against infection, preventing moisture loss, and supporting regeneration. Ceramides, integral components of the lipid matrix, are known to improve skin hydration, reduce inflammation, and accelerate wound healing. However, research on ceramide-based formulations in post-procedural settings remains limited.

aimsThis study aims to evaluate the efficacy of Aestura ATOBARRIER 365 Cream, containing a Lipid Complex with ceramides, cholesterol, and fatty acids, in promoting skin barrier recovery and improving outcomes after barrier disruption.

methodsA randomized, double-blind, split-face trial was conducted with 30 participants aged 22-60 years. Following microneedling, the active formulation was applied to one side of the face and the vehicle formulation to the other, twice daily for 4 weeks. Transepidermal Water Loss (TEWL), erythema, and roughness were measured at baseline, post-application, and at weeks 2 and 4. Participant surveys assessed moisturization, erythema, and overall skin improvement.

resultsBoth formulations demonstrated significant reductions in TEWL (14%-16%) and erythema (~1.7%) by week 4 compared to post-microneedling. High participant satisfaction was also observed, with 93% reporting improved adequate skin hydration and 90% reporting reduced erythema with the active formulation.

conclusionsAestura ATOBARRIER 365 Cream with ceramides demonstrated efficacy in improving skin barrier recovery, reducing TEWL, and enhancing skin texture following microneedling. The significant reductions in TEWL, erythema, and roughness highlight its ability to restore the skin's barrier, calm irritation, and refine texture. These findings confirm its role in supporting skin recovery and resilience after dermatological treatments, making it a valuable addition to post-procedure care. While these results support its effectiveness in post-procedural recovery, further research is needed to determine its applicability for other conditions involving compromised skin barriers, such as eczema or rosacea. Additional studies are also warranted to assess long-term efficacy and its potential role in optimizing skin barrier restoration across diverse patient populations.

Indexed as

CeramidesDry NeedlingSkin CreamAdministration, CutaneousAdultCholesterolDouble-Blind MethodErythemaFatty AcidsFemaleHumansMaleMiddle AgedPatient SatisfactionSkinTreatment OutcomeCeramidesCholesterolFatty Acidsceramidesskin barrierTransepidermal water losswound healing

Identifiers

PMID40099382
PMCPMC11915079

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.